Share Price and Basic Stock Data
Last Updated: December 26, 2025, 10:50 pm
| PEG Ratio | 64.97 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bandaram Pharma Packtech Ltd operates in the Paper & Paper Products industry, with its shares priced at ₹26.8 and a market capitalization of ₹48.2 Cr. The company has demonstrated significant revenue growth over recent quarters. In FY 2023, sales recorded a total of ₹18.73 Cr, which rose to ₹34.08 Cr in FY 2024, and further increased to ₹36.96 Cr in FY 2025. The trailing twelve months (TTM) sales stood at ₹40.31 Cr, indicating a robust upward trend. The quarterly sales figures also reflect this growth, with a peak of ₹13.43 Cr reported in March 2024. However, sales dipped to ₹7.11 Cr in September 2024, highlighting potential volatility. The company’s operational performance, as indicated by the operating profit margin (OPM), varied between 3.68% and 15.33% during the reported periods, suggesting fluctuating operational efficiency.
Profitability and Efficiency Metrics
Profitability metrics for Bandaram Pharma Packtech Ltd reveal a mixed performance. The net profit for FY 2025 was ₹0.99 Cr, with an earnings per share (EPS) of ₹0.82, reflecting an increase from ₹0.12 in FY 2023. The operating profit margin (OPM) averaged 7.66% in FY 2025, which is relatively low compared to the industry average, indicating room for improvement in cost management. The company’s return on equity (ROE) stood at 7.94%, while return on capital employed (ROCE) recorded at 7.67%, both signaling moderate efficiency in utilizing shareholder funds. The cash conversion cycle (CCC) lengthened to 185.27 days, which is considerably high, potentially indicating inefficiencies in managing working capital. This prolonged CCC can strain liquidity, especially in competitive market conditions.
Balance Sheet Strength and Financial Ratios
Bandaram Pharma Packtech Ltd’s balance sheet reflects significant borrowings of ₹21.89 Cr against reserves of ₹0.80 Cr, indicating a high debt-to-equity ratio of 1.36. This ratio raises concerns about financial leverage and the company’s ability to service its debt, especially given its interest coverage ratio of 2.95, which is below a healthy threshold. The total assets stood at ₹40.36 Cr, with liabilities also increasing, suggesting a growing financial burden. The book value per share has decreased from ₹17.11 in FY 2023 to ₹10.54 in FY 2025, reflecting a decline in net worth per share. Furthermore, the current ratio at 2.20 indicates adequate short-term liquidity, although the quick ratio of 1.59 suggests reliance on inventory for liquidity, which may pose risks during downturns.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bandaram Pharma Packtech Ltd indicates a strong promoter holding of 62.62%, which has seen a decline from 75% in earlier periods. This reduction may raise questions about promoter confidence among investors. The public holds 37.38% of the shares, while foreign institutional investors (FIIs) have no reported stake, and domestic institutional investors (DIIs) remain minimal at 0.00%. The total number of shareholders has increased to 5,004, suggesting growing interest from retail investors. The dividend payout ratio has shown fluctuations, with a notable 43.90% in FY 2025, which may attract income-focused investors. However, the lack of institutional backing could impact stock liquidity and investor confidence in the long term.
Outlook, Risks, and Final Insight
Looking ahead, Bandaram Pharma Packtech Ltd faces both opportunities and challenges. The consistent revenue growth indicates a potential for further expansion, particularly if the company can improve its operational efficiencies and manage its debt levels effectively. However, risks remain, including high borrowing costs, fluctuating profit margins, and a lengthy cash conversion cycle that could hinder liquidity. The declining promoter stake may also signal shifting investor sentiment. The company must focus on enhancing profitability and optimizing working capital to mitigate these risks. Should operational improvements materialize, along with effective debt management, Bandaram Pharma could enhance shareholder value significantly. Conversely, failure to address these issues may lead to continued volatility in performance and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mohit Paper Mills Ltd | 43.3 Cr. | 30.9 | 45.8/25.4 | 6.77 | 39.0 | 0.00 % | 12.0 % | 13.6 % | 10.0 |
| Gratex Industries Ltd | 5.31 Cr. | 17.5 | 28.0/14.2 | 48.2 | 12.2 | 0.00 % | 3.85 % | 2.52 % | 10.0 |
| Ganga Papers India Ltd | 93.8 Cr. | 86.9 | 114/75.1 | 62.1 | 29.0 | 0.00 % | 6.44 % | 5.19 % | 10.0 |
| Encode Packaging India Ltd | 4.01 Cr. | 12.7 | 19.0/10.8 | 10.3 | 0.00 % | 2.06 % | 2.12 % | 10.0 | |
| Cella Space Ltd | 28.2 Cr. | 14.0 | 19.3/9.11 | 29.4 | 10.3 | 0.00 % | 10.7 % | % | 10.0 |
| Industry Average | 757.00 Cr | 77.12 | 47.55 | 107.44 | 0.73% | 9.32% | 134.80% | 6.50 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.91 | 2.37 | 5.40 | 10.06 | 5.87 | 7.36 | 7.36 | 13.43 | 11.37 | 7.11 | 10.00 | 8.49 | 8.10 |
| Expenses | 1.11 | 2.28 | 4.65 | 9.69 | 5.34 | 6.89 | 6.89 | 12.70 | 10.83 | 6.02 | 9.34 | 7.95 | 7.47 |
| Operating Profit | -0.20 | 0.09 | 0.75 | 0.37 | 0.53 | 0.47 | 0.47 | 0.73 | 0.54 | 1.09 | 0.66 | 0.54 | 0.63 |
| OPM % | -21.98% | 3.80% | 13.89% | 3.68% | 9.03% | 6.39% | 6.39% | 5.44% | 4.75% | 15.33% | 6.60% | 6.36% | 7.78% |
| Other Income | 0.00 | 0.00 | 0.02 | 0.17 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 |
| Interest | 0.06 | 0.10 | 0.14 | 0.13 | 0.28 | 0.17 | 0.17 | 0.32 | 0.21 | 0.26 | 0.24 | -0.10 | 0.46 |
| Depreciation | 0.05 | 0.24 | 0.19 | 0.10 | 0.18 | 0.18 | 0.18 | 0.19 | 0.15 | 0.15 | 0.15 | 0.53 | 0.13 |
| Profit before tax | -0.31 | -0.25 | 0.44 | 0.31 | 0.07 | 0.12 | 0.12 | 0.25 | 0.18 | 0.68 | 0.27 | 0.20 | 0.04 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 24.00% | 0.00% | 0.00% | 103.70% | 25.00% | 25.00% |
| Net Profit | -0.32 | -0.25 | 0.43 | 0.31 | 0.07 | 0.12 | 0.12 | 0.19 | 0.18 | 0.67 | -0.01 | 0.15 | 0.02 |
| EPS in Rs | -0.27 | -0.21 | 0.36 | 0.26 | 0.06 | 0.10 | 0.10 | 0.16 | 0.15 | 0.56 | -0.01 | 0.12 | 0.02 |
Last Updated: August 19, 2025, 10:40 pm
Below is a detailed analysis of the quarterly data for Bandaram Pharma Packtech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 8.10 Cr.. The value appears to be declining and may need further review. It has decreased from 8.49 Cr. (Mar 2025) to 8.10 Cr., marking a decrease of 0.39 Cr..
- For Expenses, as of Jun 2025, the value is 7.47 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.95 Cr. (Mar 2025) to 7.47 Cr., marking a decrease of 0.48 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.63 Cr.. The value appears strong and on an upward trend. It has increased from 0.54 Cr. (Mar 2025) to 0.63 Cr., marking an increase of 0.09 Cr..
- For OPM %, as of Jun 2025, the value is 7.78%. The value appears strong and on an upward trend. It has increased from 6.36% (Mar 2025) to 7.78%, marking an increase of 1.42%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.09 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.09 Cr..
- For Interest, as of Jun 2025, the value is 0.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from -0.10 Cr. (Mar 2025) to 0.46 Cr., marking an increase of 0.56 Cr..
- For Depreciation, as of Jun 2025, the value is 0.13 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.53 Cr. (Mar 2025) to 0.13 Cr., marking a decrease of 0.40 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 0.20 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.16 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00%.
- For Net Profit, as of Jun 2025, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.15 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.13 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.02. The value appears to be declining and may need further review. It has decreased from 0.12 (Mar 2025) to 0.02, marking a decrease of 0.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:06 am
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Sales | 0.00 | 18.73 | 34.08 | 36.96 | 40.31 |
| Expenses | 0.01 | 17.58 | 31.26 | 34.13 | 38.03 |
| Operating Profit | -0.01 | 1.15 | 2.82 | 2.83 | 2.28 |
| OPM % | 6.14% | 8.27% | 7.66% | 5.66% | |
| Other Income | 0.00 | 0.19 | 0.03 | 0.09 | 0.10 |
| Interest | 0.00 | 0.43 | 0.93 | 0.99 | 0.85 |
| Depreciation | 0.00 | 0.59 | 0.73 | 0.61 | 0.95 |
| Profit before tax | -0.01 | 0.32 | 1.19 | 1.32 | 0.58 |
| Tax % | 0.00% | 21.88% | 20.17% | 24.24% | |
| Net Profit | -0.01 | 0.26 | 0.95 | 0.99 | 0.22 |
| EPS in Rs | -0.01 | 0.12 | 0.79 | 0.82 | 0.18 |
| Dividend Payout % | 0.00% | 21.43% | 12.63% | 12.12% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 2700.00% | 265.38% | 4.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2434.62% | -261.17% |
Bandaram Pharma Packtech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 366% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 68% |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 7% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 2:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:29 am
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|
| Equity Capital | 7.06 | 3.00 | 12.00 | 12.00 | 12.00 |
| Reserves | -0.06 | 0.08 | 0.28 | 0.65 | 0.80 |
| Borrowings | 0.00 | 14.20 | 12.20 | 17.15 | 21.89 |
| Other Liabilities | 0.48 | 2.90 | 7.58 | 9.12 | 5.67 |
| Total Liabilities | 7.48 | 20.18 | 32.06 | 38.92 | 40.36 |
| Fixed Assets | 2.87 | 5.03 | 4.48 | 3.95 | 3.69 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 2.09 | 0.00 | 1.40 | 1.40 | 1.40 |
| Other Assets | 2.52 | 15.15 | 26.18 | 33.57 | 35.27 |
| Total Assets | 7.48 | 20.18 | 32.06 | 38.92 | 40.36 |
Below is a detailed analysis of the balance sheet data for Bandaram Pharma Packtech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00 Cr..
- For Reserves, as of Sep 2025, the value is 0.80 Cr.. The value appears strong and on an upward trend. It has increased from 0.65 Cr. (Mar 2025) to 0.80 Cr., marking an increase of 0.15 Cr..
- For Borrowings, as of Sep 2025, the value is 21.89 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 17.15 Cr. (Mar 2025) to 21.89 Cr., marking an increase of 4.74 Cr..
- For Other Liabilities, as of Sep 2025, the value is 5.67 Cr.. The value appears to be improving (decreasing). It has decreased from 9.12 Cr. (Mar 2025) to 5.67 Cr., marking a decrease of 3.45 Cr..
- For Total Liabilities, as of Sep 2025, the value is 40.36 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.92 Cr. (Mar 2025) to 40.36 Cr., marking an increase of 1.44 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.69 Cr.. The value appears to be declining and may need further review. It has decreased from 3.95 Cr. (Mar 2025) to 3.69 Cr., marking a decrease of 0.26 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 1.40 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.40 Cr..
- For Other Assets, as of Sep 2025, the value is 35.27 Cr.. The value appears strong and on an upward trend. It has increased from 33.57 Cr. (Mar 2025) to 35.27 Cr., marking an increase of 1.70 Cr..
- For Total Assets, as of Sep 2025, the value is 40.36 Cr.. The value appears strong and on an upward trend. It has increased from 38.92 Cr. (Mar 2025) to 40.36 Cr., marking an increase of 1.44 Cr..
However, the Borrowings (21.89 Cr.) are higher than the Reserves (0.80 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Free Cash Flow | -0.01 | -13.05 | -9.38 | -14.32 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Debtor Days | 129.01 | 155.51 | 185.27 | |
| Inventory Days | ||||
| Days Payable | ||||
| Cash Conversion Cycle | 129.01 | 155.51 | 185.27 | |
| Working Capital Days | 147.13 | 147.59 | 165.22 | |
| ROCE % | 5.69% | 9.10% | 7.67% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.83 | 0.81 | 0.47 |
| Diluted EPS (Rs.) | 0.83 | 0.81 | 0.47 |
| Cash EPS (Rs.) | 1.34 | 1.40 | 2.81 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 10.54 | 10.23 | 17.11 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 10.54 | 10.23 | 17.11 |
| Revenue From Operations / Share (Rs.) | 30.80 | 28.40 | 62.44 |
| PBDIT / Share (Rs.) | 2.43 | 2.38 | 4.48 |
| PBIT / Share (Rs.) | 1.92 | 1.77 | 2.53 |
| PBT / Share (Rs.) | 1.10 | 0.98 | 1.09 |
| Net Profit / Share (Rs.) | 0.82 | 0.78 | 0.85 |
| NP After MI And SOA / Share (Rs.) | 0.45 | 0.43 | 0.47 |
| PBDIT Margin (%) | 7.88 | 8.36 | 7.16 |
| PBIT Margin (%) | 6.23 | 6.22 | 4.04 |
| PBT Margin (%) | 3.56 | 3.48 | 1.73 |
| Net Profit Margin (%) | 2.68 | 2.78 | 1.37 |
| NP After MI And SOA Margin (%) | 1.47 | 1.52 | 0.75 |
| Return on Networth / Equity (%) | 4.32 | 4.24 | 4.59 |
| Return on Capital Employeed (%) | 9.25 | 10.69 | 5.90 |
| Return On Assets (%) | 1.40 | 1.62 | 0.70 |
| Long Term Debt / Equity (X) | 0.71 | 0.38 | 2.48 |
| Total Debt / Equity (X) | 1.36 | 0.99 | 4.61 |
| Asset Turnover Ratio (%) | 1.04 | 1.30 | 0.00 |
| Current Ratio (X) | 2.20 | 2.13 | 2.05 |
| Quick Ratio (X) | 1.59 | 1.60 | 1.68 |
| Inventory Turnover Ratio (X) | 4.94 | 6.56 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 43.90 | 0.00 | 84.68 |
| Dividend Payout Ratio (CP) (%) | 20.70 | 0.00 | 16.51 |
| Earning Retention Ratio (%) | 56.10 | 0.00 | 15.32 |
| Cash Earning Retention Ratio (%) | 79.30 | 0.00 | 83.49 |
| Interest Coverage Ratio (X) | 2.95 | 3.05 | 3.11 |
| Interest Coverage Ratio (Post Tax) (X) | 2.01 | 2.01 | 1.60 |
| Enterprise Value (Cr.) | 75.85 | 59.42 | 37.98 |
| EV / Net Operating Revenue (X) | 2.05 | 1.74 | 2.03 |
| EV / EBITDA (X) | 26.01 | 20.85 | 28.28 |
| MarketCap / Net Operating Revenue (X) | 1.51 | 1.30 | 1.17 |
| Retention Ratios (%) | 56.09 | 0.00 | 15.31 |
| Price / BV (X) | 4.40 | 3.62 | 7.10 |
| Price / Net Operating Revenue (X) | 1.51 | 1.30 | 1.17 |
| EarningsYield | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Bandaram Pharma Packtech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 5. It has increased from 0.81 (Mar 24) to 0.83, marking an increase of 0.02.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 5. It has increased from 0.81 (Mar 24) to 0.83, marking an increase of 0.02.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 3. It has decreased from 1.40 (Mar 24) to 1.34, marking a decrease of 0.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.54. It has increased from 10.23 (Mar 24) to 10.54, marking an increase of 0.31.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.54. It has increased from 10.23 (Mar 24) to 10.54, marking an increase of 0.31.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 30.80. It has increased from 28.40 (Mar 24) to 30.80, marking an increase of 2.40.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.43. This value is within the healthy range. It has increased from 2.38 (Mar 24) to 2.43, marking an increase of 0.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.77 (Mar 24) to 1.92, marking an increase of 0.15.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.10. This value is within the healthy range. It has increased from 0.98 (Mar 24) to 1.10, marking an increase of 0.12.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 2. It has increased from 0.78 (Mar 24) to 0.82, marking an increase of 0.04.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 2. It has increased from 0.43 (Mar 24) to 0.45, marking an increase of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 7.88. This value is below the healthy minimum of 10. It has decreased from 8.36 (Mar 24) to 7.88, marking a decrease of 0.48.
- For PBIT Margin (%), as of Mar 25, the value is 6.23. This value is below the healthy minimum of 10. It has increased from 6.22 (Mar 24) to 6.23, marking an increase of 0.01.
- For PBT Margin (%), as of Mar 25, the value is 3.56. This value is below the healthy minimum of 10. It has increased from 3.48 (Mar 24) to 3.56, marking an increase of 0.08.
- For Net Profit Margin (%), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 5. It has decreased from 2.78 (Mar 24) to 2.68, marking a decrease of 0.10.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 8. It has decreased from 1.52 (Mar 24) to 1.47, marking a decrease of 0.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.32. This value is below the healthy minimum of 15. It has increased from 4.24 (Mar 24) to 4.32, marking an increase of 0.08.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.25. This value is below the healthy minimum of 10. It has decreased from 10.69 (Mar 24) to 9.25, marking a decrease of 1.44.
- For Return On Assets (%), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 5. It has decreased from 1.62 (Mar 24) to 1.40, marking a decrease of 0.22.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has increased from 0.38 (Mar 24) to 0.71, marking an increase of 0.33.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.36. This value exceeds the healthy maximum of 1. It has increased from 0.99 (Mar 24) to 1.36, marking an increase of 0.37.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.04. It has decreased from 1.30 (Mar 24) to 1.04, marking a decrease of 0.26.
- For Current Ratio (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.20, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has decreased from 1.60 (Mar 24) to 1.59, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.94. This value is within the healthy range. It has decreased from 6.56 (Mar 24) to 4.94, marking a decrease of 1.62.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 43.90. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 43.90, marking an increase of 43.90.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.70. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 20.70, marking an increase of 20.70.
- For Earning Retention Ratio (%), as of Mar 25, the value is 56.10. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 56.10, marking an increase of 56.10.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.30. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 79.30, marking an increase of 79.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 3. It has decreased from 3.05 (Mar 24) to 2.95, marking a decrease of 0.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.01. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 2.01.
- For Enterprise Value (Cr.), as of Mar 25, the value is 75.85. It has increased from 59.42 (Mar 24) to 75.85, marking an increase of 16.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.05. This value is within the healthy range. It has increased from 1.74 (Mar 24) to 2.05, marking an increase of 0.31.
- For EV / EBITDA (X), as of Mar 25, the value is 26.01. This value exceeds the healthy maximum of 15. It has increased from 20.85 (Mar 24) to 26.01, marking an increase of 5.16.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.51, marking an increase of 0.21.
- For Retention Ratios (%), as of Mar 25, the value is 56.09. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 56.09, marking an increase of 56.09.
- For Price / BV (X), as of Mar 25, the value is 4.40. This value exceeds the healthy maximum of 3. It has increased from 3.62 (Mar 24) to 4.40, marking an increase of 0.78.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.51, marking an increase of 0.21.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bandaram Pharma Packtech Ltd:
- Net Profit Margin: 2.68%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.25% (Industry Average ROCE: 9.32%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.32% (Industry Average ROE: 134.8%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.01
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.59
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 230 (Industry average Stock P/E: 47.55)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.36
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.68%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Paper & Paper Products | 601,5th Floor, Oxford Towers, Opp to Leela Palace Hotel, Bangalore Karnataka 560008 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. B Deepak Reddy | Chairman & Managing Director |
| Mr. Nadella Srinivasula Kalki Aakarsh Raj | Whole Time Director |
| Mr. B Premsai Reddy | Non Executive Director |
| Ms. B Sathyavathi | Non Executive Director |
| Mr. B Suryaprakasa Rao | Independent Director |
| Ms. Priyanka Agarwal | Independent Director |
| Mr. Suman Mallu | Independent Director |
| Ms. Mounika Pammi | Independent Director |
FAQ
What is the intrinsic value of Bandaram Pharma Packtech Ltd?
Bandaram Pharma Packtech Ltd's intrinsic value (as of 26 December 2025) is 156.89 which is 458.33% higher the current market price of 28.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 50.6 Cr. market cap, FY2025-2026 high/low of 52.0/22.8, reserves of ₹0.80 Cr, and liabilities of 40.36 Cr.
What is the Market Cap of Bandaram Pharma Packtech Ltd?
The Market Cap of Bandaram Pharma Packtech Ltd is 50.6 Cr..
What is the current Stock Price of Bandaram Pharma Packtech Ltd as on 26 December 2025?
The current stock price of Bandaram Pharma Packtech Ltd as on 26 December 2025 is 28.1.
What is the High / Low of Bandaram Pharma Packtech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bandaram Pharma Packtech Ltd stocks is 52.0/22.8.
What is the Stock P/E of Bandaram Pharma Packtech Ltd?
The Stock P/E of Bandaram Pharma Packtech Ltd is 230.
What is the Book Value of Bandaram Pharma Packtech Ltd?
The Book Value of Bandaram Pharma Packtech Ltd is 10.7.
What is the Dividend Yield of Bandaram Pharma Packtech Ltd?
The Dividend Yield of Bandaram Pharma Packtech Ltd is 0.36 %.
What is the ROCE of Bandaram Pharma Packtech Ltd?
The ROCE of Bandaram Pharma Packtech Ltd is 7.67 %.
What is the ROE of Bandaram Pharma Packtech Ltd?
The ROE of Bandaram Pharma Packtech Ltd is 7.94 %.
What is the Face Value of Bandaram Pharma Packtech Ltd?
The Face Value of Bandaram Pharma Packtech Ltd is 10.0.